We have been developing a unique system for the downregulation of a gene expression through cutting a specific mRNA by the long form of tRNA 3 0 -processing endoribonuclease (tRNase Z L ) under the direction of small-guide RNA (sgRNA). However, the efficacy of this system and the involvement of tRNase Z L in the living cells were not clear. Here we show, by targeting the exogenous luciferase gene, that the efficacy of the sgRNA/tRNase Z L method can become comparable to that of the RNA interference technology and that the gene silencing is owing to tRNase Z L directed by sgRNA not owing to a simple antisense effect. We also show that tRNase Z L together with sgRNA can downregulate expression of the endogenous human genes Bcl-2 and glycogen synthase kinase-3b by degrading their mRNAs in cell culture. Furthermore, we demonstrate that a gene expression in the livers of postnatal mice can be inhibited by an only seven-nucleotide sgRNA. These data suggest that sgRNA might be utilized as therapeutic agents to treat diseases such as cancers and AIDS.
Introduction
The tRNAs are transcribed as larger precursor molecules, which subsequently undergo various processing steps such as removal of 5 0 and 3 0 extra sequences to generate mature tRNAs. 1 tRNase Z is one of the tRNA-maturing enzymes, which removes a 3 0 trailer from pre-tRNA. [2] [3] [4] Most tRNase Zs cleave pre-tRNAs immediately downstream of a discriminator nucleotide, onto which the CCA residues are added to produce mature tRNA, whereas tRNase Z from Thermotoga maritima exceptionally cleaves pre-tRNAs containing the CCA sequence precisely after the A residue to create the mature 3 0 -termini. 5 tRNase Zs can be divided into two groups: a short form (tRNase Z S ) that consists of 300-400 amino acids and a long form (tRNase Z L ) that contains 800-900 amino acids. 6 Bacteria and archaea genomes contain a tRNase Z S gene only, whereas eucaryotic genomes encode either only tRNase Z L or both forms. Interestingly, the human tRNase Z L is encoded by a prostate cancer-associated gene on chromosome 17, 7 and the human tRNase Z S gene is on chromosome 18. The C-terminal half region of tRNase Z L has high similarity to the whole region of tRNase Z S and these regions contain a well-conserved histidine motif, which has been shown to be essential for the tRNase Z activity. 5, 8 We have demonstrated in vitro that mammalian tRNase Z L can cleave any target RNA at any desired site by recognizing a pre-tRNA-like or micro-pre-tRNAlike complex formed between the target RNA and artificial small-guide RNA (sgRNA). [9] [10] [11] [12] sgRNA is divided into four categories: 5 0 -half-tRNA, 10 14-nucleotide (nt) linear RNA, 13 RNA heptamer 11, 12 and hook RNA. 14 For example, with the aid of appropriate 5 0 -half-tRNAs, the two partial HIV-1 RNA targets ENV and GAG were cleaved site-specifically by tRNase Z L . 10 A 14-nt linear RNA guided target RNA cleavage by tRNase Z L through forming a 14 base pair (bp) double-stranded RNA. 13 Amazingly, tRNase Z L can also recognize a 12-bp hairpin RNA complex between a separate target RNA and an RNA heptamer, and cleave the target. 11, 12 In this case, however, the target sites are restricted to immediate downstream regions of stable hairpin structures resembling the T stem/loop. This is advantageous because a heptamer can direct efficient RNA cleavage with a specificity of roughly 12-nt sequence and not merely a 7-nt sequence owing to the need for a stable hairpin structure. In contrast, tRNase Z S can process pre-tRNAs but not these pre-tRNA-like or micro-pre-tRNA-like complexes in vitro. 4, 6 We have shown the efficacy of this RNA-targeting method in the living cells to some degree by introducing sgRNAs either as their expression plasmids or as 2 0 -Omethyl RNAs. 15, 16 The expression of exogenous reporter genes for Escherichia coli chloramphenicol acetyltransferase (CAT) and firefly luciferase were downregulated by appropriately designed sgRNAs in mammalian culture cells, 15 and the HIV-1 expression in Jurkat cells was almost completely suppressed by a 5 0 -half-tRNA-type sgRNA up to 18 days. 16 However, the involvement of tRNase Z L in this gene silencing remained unproven. In this paper, we show that the efficacy of the sgRNA/ tRNase Z L method can become comparable to that of the RNA interference (RNAi) technology, and that the gene silencing is owing to tRNase Z L directed by sgRNA not owing to a simple antisense effect. We also demonstrate that tRNase Z L together with sgRNA can downregulate expression of the endogenous human genes Bcl-2 and glycogen synthase kinase (GSK)-3b, and that an exogenous gene expression in the livers of postnatal mice can be inhibited by an only 7-nt sgRNA. The present study suggests that the sgRNA/tRNase Z L technology might surpass the RNAi technology and that sgRNA might be utilized as therapeutic agents to treat diseases such as cancers and AIDS.
Results and discussion
The efficacy of sgRNA can become comparable to that of siRNA
To assess the efficacy of the sgRNA/tRNase Z L technology more strictly, we compared the gene-silencing level by small interfering RNA (siRNA) with those by sgRNAs by targeting the exogenous firefly luciferase gene. The two types of sgRNA 5 0 -half-tRNA and 14-nt linear RNA were designed at each of three arbitrary sites (Figure 1 ). Each 5 0 -half-tRNA consists of 7-and 5-nt sequences complementary to a sequence 5 0 to the desired cleavage site and the D arm of the human pre-tRNA Arg in between.
10 Each 5 0 -half-tRNA and the target luciferase mRNA can form a pre-tRNA-like structure through 7 and 5 base-pairings corresponding to the acceptor and anticodon stems, respectively. Each linear-type sgRNA is a 14-nt sequence complementary to a sequence 5 0 to the desired cleavage site, and can form a 14-bp doublestranded RNA with the target RNA, which roughly corresponds to a combination of the acceptor and T stems. 13 An siRNA, siRLuc, targeting downstream to one of the sites, which has been shown to work very efficiently, 17 was used as a positive control, and an unrelated 14-nt linear RNA, sgGSKL2 (5 0 -CUUAGUCCA AGGAU-3 0 ), was used as a negative control. We co-transfected human kidney 293 cells with the modified luciferase expression plasmid p5LucWT and the reference plasmid pTKb together with 0.4 mM of siRNA or each 2 0 -O-methyl sgRNA. The plasmid p5LucWT contains a modified luciferase gene that produces an mRNA containing the target site of the heptamer-type sgRNA Hep1 in the 5 0 -untranslated region, 15 and the plasmid pTKb possesses a b-galactosidase gene. All these sgRNAs except for sgLucL1 downregulated the luciferase activity very efficiently to 3.2-13.6% (Figure 2a ). The suppression levels by sgLucH2 and sgLucH3 were 3.7 and 3.2%, respectively, and comparable to that by siRLuc (3.0%). Although this result was the first to show that linear-type sgRNAs indeed work in the cells, the 5 0 -half-tRNA type was generally more effective than the 14-nt linear RNA type (Figure 2a ). Luciferase mRNA was hardly detected in Northern analysis for representative transfectants with sgLucH1 or sgLucH3, suggesting that the downregulation of luciferase activity is owing to mRNA degradation not owing to translational suppression (Figure 2b) .
We also examined how the gene-silencing level would be affected by changing the sgRNA amount using the least efficient 5 0 -half-tRNA sgLucH1. sgLucH1 was introduced into 293 cells in the range of 0.2-4.0 mM. When its amount was increased to more than 1.0 mM, even the least effective sgLucH1 became comparable to siRLuc (Figure 2c ). Taken together, these results suggest that gene-silencing efficiency of sgRNA would generally Gene silencing by tRNase Z L and sgRNA A Nakashima et al become comparable to that of siRNA as an sgRNA amount is increased.
tRNase Z L is responsible for the gene silencing by sgRNA
Although these and previous results 15, 16 indicated that appropriate sgRNAs can downregulate targeted gene expressions in the cells, no direct evidence existed demonstrating that the downregulation is owing to specific mRNA cleavage by endogenous tRNase Z L not owing to a simple antisense effect or other different mechanisms. To clarify this issue, we generated two types of stable 293 cell line, which produce more tRNase Z L or less tRNase Z L and examined silencing levels for the luciferase gene in these transfectants. If tRNase Z L is the responsible enzyme, the downregulation level should change depending on the tRNase Z L amount. The 293 cells containing a tRNase Z L cDNA controlled by a human cytomegalovirus promoter produced B2-fold more tRNase Z L , whereas the cells, in which the tRNase Z L gene was knocked down by shRNA (Supplementary Table 1 ), produced B4-fold less enzyme ( Figure 3a ). The tRNase Z S levels were not affected in these cell lines ( Figure 3a ). As controls, we also generated another two types of stable 293 cell line, which produce more tRNase Z S or less tRNase Z S together with the unaffected level of tRNase Z L ( Figure 3a ). These cell lines were created in the same way as above.
The 5 0 -half-tRNA sgLucH1 downregulated the luciferase gene expression to B14% in normal 293 cells, whereas its expression level in the cells producing more tRNase Z L went down to B2% in accordance with the expressed tRNase Z L level (Figure 3b ). On the other hand, the silencing level by sgLucH1 was relieved B7 times in the 293 cells producing B4-fold less tRNase Z L ( Figure 3b ). The downregulation level of luciferase activity by sgLucH1 was not changed very much (relieved only B1.5-fold) in the 293 cells producing more tRNase Z S or less tRNase Z S . This observation is consistent with the in vitro observation that tRNase Z S cannot cleave pre-tRNA-like complexes. 6, 13 In the same manner, the downregulation level of the luciferase activity by the linear-type sgRNA sgLucL1 was enhanced B3-fold in the tRNase Z L -overproducing cells, and was relieved B2.5-fold in the tRNase Z L -knockdown cells ( Figure 3c ). The downregulation level was enhanced only slightly (B1.3-fold) in the cell lines producing altered levels of tRNase Z S . In contrast, the silencing level by siRLuc was not affected significantly in these modified 293 cell lines (Figure 3d ). From these results, we concluded that the gene silencing is attributed to tRNase Z L directed by sgRNA. To see if longer linear-type RNAs, which cannot guide RNA cleavage by tRNase Z L in vitro, 13 affect gene expressions, we tested the 21-and 28-nt linear-type RNAs for luciferase gene silencing (Figure 4a) . A plasmid that can express the linear-type RNA from a mouse U6 promoter was co-transfected into the 293 cells together with the reporter and reference plasmids. Consistent with the in vitro observation, the 21-and 28-nt linear-type RNAs did not downregulate the luciferase activity, whereas the sgRNAs sgLucH1 and sgLucL1 did so (Figure 4b ). This result supports the involvement of tRNase Z L in gene silencing by sgRNA. Under different conditions or by targeting different sites, however, even longer linear-type RNA could repress a gene expression to some degree by a simple antisense effect as previously observed using a 25-nt linear-type RNA targeting the CAT mRNA. 15 The reason why the downregulation level by sgLucH1 from the expression plasmid was lower than that by 2 0 -O-methyl sgLucH1 (Figures 2a and 4b ) may be because the effective sgRNA amount in the cells was lower owing to its instability.
Downregulation of the Bcl-2 expression
To further confirm the efficacy of the sgRNA/tRNase Z L technology, we targeted an endogenous gene, Bcl-2.
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Although we have shown that a heptamer-type sgRNAtargeting mouse Bcl-2 mRNA causes a reduction in Sarcoma 180 cell viability, there was no direct evidence showing degradation of the Bcl-2 mRNA because neither Bcl-2 mRNA nor protein amount was checked. 15 We designed the 5 0 -half-tRNA sgBclH and the 14-nt linear RNA sgBclL to target human Bcl-2 mRNA (Figure 5a ) and generated stable 293 cell lines that produce either of these sgRNAs from a human H1 promoter. Gene silencing by tRNase Z L and sgRNA A Nakashima et al
The Bcl-2 mRNA and protein levels were reduced intensively in both transfectants (Figure 5b and c) , indicating that the Bcl-2 downregulation is owing to degradation of its mRNA not owing to translational suppression. As a result, apoptosis of both 293 transfectants was induced by removing sera from culture media more efficiently (B2-fold by sgBclH and B1.5-fold by sgBclL) than normal 293 cells (Figure 5d ). The increase in apoptosis rate was also observed in four stable transfectants producing one of four different sgRNAs targeting two other sites of Bcl-2 mRNA (data not shown). These results indicate that sgRNA generated from an exogenous plasmid also functions to downregulate an endogenous gene expression. Gene silencing by tRNase Z L and sgRNA A Nakashima et al
GSK-3b silencing
We also targeted another endogenous human gene, GSK3b, which encodes an evolutionarily conserved serinethreonine kinase involved in several cellular signaling pathways. 19 The 5 0 -half-tRNA sgGSKH and the 14-nt linear RNA sgGSKL for GSK-3b mRNA targeting were designed (Figure 6a) , and stable 293 transfectants that produce either of these sgRNAs from the H1 promoter were generated. In both transfectants, the GSK-3b protein level was drastically decreased, whereas the mRNA level was decreased to only B43% (Figure 6b and c) . This suggests that the decrease in the protein amount would be not only owing to degradation of its mRNA but also partly owing to translational suppression. Because suppression of the GSK-3b protein level leads to the upregulation of a Lef1/Tcf transcriptional factor, we can monitor the GSK-3b protein level by using the luciferase expression plasmid TOPflash that contains the Lef1/Tcfbinding sites. By co-transfecting TOPflash with 2 0 -Omethyl sgGSKH or sgGSKL into normal 293 cells, the luciferase activity was augmented to B140-150% (Figure  6d ), corroborating the efficacy of these sgRNAs in silencing the endogenous GSK-3b gene.
Gene silencing in postnatal mice
To see whether sgRNAs can function to inhibit gene expressions in organs of postnatal mice, we introduced an sgRNA expression plasmid together with the CAT expression plasmid pcDNA3/CAT and the reference plasmid pGL3-control into mice through the hydrodynamics gene transfer method. 19, 20 The sgRNA expression plasmid psgCAT generates the sgRNA sgCAT from the tRNA Arg promoter, which is designed to direct the CAT mRNA cleavage at 222 nucleotides downstream from the initiation codon (Figure 7a) . 15 The negative control plasmid psgCATM expresses a similar sgRNA, which, however, contains 7-nt substitutions and virtually cannot bind to the CAT mRNA. The CAT protein level in the livers of mice injected with psgCAT was reduced B4-fold compared to that with psgCATM ( Figure 7b ). This result closely parallels what we observed in the transfection experiment with Madin-Darby canine kidney cells, 15 and indicates that sgRNA indeed works to suppress a gene expression in postnatal mice.
Gene silencing by an RNA heptamer in mice
We also examined whether heptamer-type sgRNA can function to knockdown a specific mRNA in animals by testing a 2 0 -O-methyl RNA heptamer that targets the luciferase mRNA for reduction of its activity. The heptamer Hep1, Hep2 or Bclhep was injected into mice together with the modified luciferase expression plasmid p5LucWT and the reference plasmid pcDNA3/CAT. Hep1 is complementary to the 7-nt target sequence in the 5 0 -untranslated region of the luciferase mRNA and can form a perfect 12-bp stem-loop complex with the modified luciferase mRNA, whereas Hep2 contains three nt substitutions (Figure 7a) , and Bclhep has an unrelated sequence (5 0 -GGGGGCA-3 0 ), as expected from the observations in the cell culture experiment. 15 Hep1 injection into mice downregulated the luciferase activity Gene silencing by tRNase Z L and sgRNA A Nakashima et al B4-fold relative to Hep2 or Bclhep injection (Figure 7c) , indicating the efficacy of heptamer-type sgRNA in postnatal mice.
To examine whether the downregulation by the RNA heptamer is also through mRNA cleavage by tRNase Z L , we compared the downregulation level in normal 293 cells with those in modified 293 cells producing more tRNase Z L or less tRNase Z L . The downregulation level was augmented B8-fold in the tRNase Z L -overproducing cell line and relieved B2.3-fold in the tRNase Z L -knockdown cell line (Figure 7d ). In contrast, the downregulation level was not changed significantly in the 293 cells producing more tRNase Z S or less tRNase Z S . These results confirm the involvement of tRNase Z L in the heptamer-directed gene silencing. The small size of heptamer RNA would provide some advantages: heptamers can be taken up readily by living cells without the use of stimulating reagents such as cationic liposomes, and are much easier and cheaper to synthesize than long oligomers such as siRNA.
Another role of tRNase Z L
Here, we convincingly demonstrated that, under the direction of sgRNA, tRNase Z L can downregulate a gene expression by eliminating its mRNA. This, together with the fact that tRNase Z L has the extra N-terminal region that is dispensable for pre-tRNA processing, 4, 6 implies an additional role of this enzyme. There exist a huge number of microRNAs (miRNAs) that are believed to work as translational regulators, 21 and, curiously, their length is B21-23 nt, which is similar to the length of hook-type sgRNA. These observations suggest that some of the miRNAs could work as hook RNA that directs cellular RNA cleavage by tRNase Z L , although there is no direct evidence yet.
Over the RNAi technology
As we showed, the efficacy of the sgRNA/tRNase Z L technology can become comparable to that of the RNAi technology. In addition, sgRNA has some advantages over siRNA. sgRNA would never trigger interferon response and a subsequent translational shutdown. 22 A potential off-target effect of sgRNA would be much less serious than that of siRNA because the length of an sgRNA sequence complementary to target RNA is only 7-14 nt, much smaller than siRNAs' length of B21-23 nt. 22 sgRNA, especially the 14-nt linear type, could be used to cleave and eliminate even miRNA to elucidate each miRNA's function, whereas siRNA could not judging from the RNAi mechanism. These considera- Gene silencing by tRNase Z L and sgRNA A Nakashima et al tions suggest that the sgRNA/tRNase Z L technology might partly take over the siRNAs' job, and that sgRNA might be utilized as therapeutic agents to treat diseases such as cancers and AIDS.
Materials and methods

RNA
The 5 0 -phosphorylated 2 0 -O-methyl RNAs and the siRNA siRLuc were synthesized with a DNA/RNA synthesizer and purified by high-performance liquid chromatography (Nippon Bioservice, Asaka, Saitama, Japan).
Plasmid construction
The tRNase Z L and tRNase Z S expression plasmids were generated by cloning their cDNAs 4 into pcDNA4/TO/ myc-His (Invitrogen, Carlsbad, CA, USA). The shRNA expression plasmids for silencing the tRNase Z L and tRNase Z S genes and the sgRNA expression plasmids for silencing Bcl-2 and GSK-3b genes were constructed by inserting annealed synthetic oligonucleotides (Supplementary Table 1 ) between BamHI and HindIII sites of pRNATin-H1.2/Neo (GenScript, Piscataway, NJ, USA). Plasmids for expression of sgLucH1, sgLucL1, LucL21 and LucL28 were constructed by inserting annealed synthetic DNA oligonucleotides (Supplementary Table 1) between ApaI and EcoRI sites of pSilencer 1.0-U6 (Ambion, Austin, TX, USA). The primary transcripts from pRNATin-H1.2/Neo and pSilencer 1.0-U6 were designed to include a 3 0 uridine stretch corresponding to the RNA polymerase III terminator.
Cell culture
The human kidney 293 cells were cultured in Dulbecco's modified Eagle's medium (Sigma, St Louis, MO, USA) supplemented with 10% fetal bovine serum (MP Biomedicals, Irvine, CA, USA) and 1% penicillin-streptomycin (Invitrogen) at 371C in a 5% CO 2 humidified incubator.
Transfection
The 293 cells were transfected with plasmids or with plasmids and 2 0 -O-methyl sgRNA using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. To generate stable transfectants that possess a gene controlled by a tetracycline-inducible promoter, we cotransfected the 293 cells with a plasmid from pcDNA4/ TO/myc-His or from pRNATin-H1.2/Neo together with the tetracycline repressor expression plasmid pcDNA6/ TR (Invitrogen). Stable transfectants were selected and cultured in the presence of 2 mg/ml of blasticidin (Invitrogen) and 50 mg/ml of zeocin (Invitrogen) or 500 mg/ml of geneticin (MP Biomedicals). Although the gene expression from the tetracycline-inducible promoter was observed even in the absence of tetracycline, it was added at 3 mg/ml to culture media to ensure the expression.
Luciferase assays and CAT assays
These assays were performed basically as described before. 15 In culture cell experiments, the modified luciferase expression plasmid p5LucWT 15 and the luciferase plasmid TOPflash (Upstate Biotechnology, Lake Placid, NY, USA) were used as reporters, and the b-galactosidase expression plasmid pTKb (Clontech, Palo Alto, CA, USA) was used as a reference.
Northern analysis
Total RNA (20 mg/lane), extracted from 293 cells with ISOGEN (Nippon Gene, Toyama, Japan), was separated by formaldehyde/1% agarose gel electrophoresis, and transferred to a nitrocellulose membrane. Hybridization with digoxigenin-labeled RNA probes and detection were performed according to the manufacturer's protocol (Roche Diagnostics, Minato-Ku, Tokyo, Japan). The entire luciferase coding region, the 3 0 -untranslated region (2016-2680 nt 3 0 to the stop codon) of human Bcl-2 mRNA, and the entire coding region of human glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) were used as probes to measure the levels of luciferase mRNA, Bcl-2 mRNA and GAPDH mRNA, respectively.
Real-time reverse transcriptase-polymerase chain reaction cDNA synthesis for 1 mg of total RNA was carried out using Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics). Real-time polymerase chain reaction for the cDNA was performed using the LightCycler FastStart DNA Master PLUS SYBR Green I kit according to the manufacturer's protocol (Roche Diagnostics). The primers for amplifying a 120-bp fragment of GSK-3b cDNA were 5 0 -TGCATTAAGCACCTGCGC-3 0 and 5 0 -AG CAGGACAGCCACTCTCC-3 0 , 23 and the primers for amplifying a 187-bp fragment of GAPDH cDNA were 5 0 -ACCCACTCCTCCACCTTTG-3 0 and 5 0 -CTCTTGTGC TCTTGCTGGG-3 0 .
Western analysis
Whole-cell extracts, dissolved in a buffer (50 mM TrisHCl (pH 6.8), 2% SDS, 10% glycerol, 100 mM dithiothreitol), were separated by SDS/10% polyacrylamide gel electrophoresis, transferred to a nitrocellulose membrane and probed with anti-Bcl-2 or anti-GSK-3b antibodies (BD biosciences, Palo Alto, CA, USA) or antibodies raised to a human tRNase Z L peptide (amino acids 812-826) or recombinant human tRNase Z S using the ECL Western Blotting Detection System (Amersham Biosciences, Piscataway, NJ, USA).
Measurement of cell numbers
The living cell number was measured using TetraColor ONE (Seikagaku, Chiyoda-ku, Tokyo, Japan) according to the manufacturer's protocol.
Hydrodynamics-based transfection
Four-week-old JcI:ICR female mice (18-20 g) were coinjected through the hydrodynamics-based gene transfer method, 20, 24 with a 1.5-ml buffer containing 5 mg of pcDNA3/CAT (Invitrogen), 5 mg of pGL3-control (Promega, Madison, WI, USA) (or p5LucWT for luciferase targeting) and 5 mg of psgCAT or psgCATM (or 3 nmol of the 2 0 -O-methyl RNA heptamer Hep1, Hep2 or Bclhep for luciferase targeting). The CAT protein amounts and the luciferase activities in mouse liver extracts were measured 8 h after injection. These experiments were carried out in accordance with the guidelines on the care and use of laboratory animals issued by Hokkaido University.
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